Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: TRC105|DRUG: Capecitabine
Sponsor: Tracon Pharmaceuticals Inc.
Collaborators: Roswell Park Cancer Institute|United States Department of Defense